Compare · LGVN vs NVO
LGVN vs NVO
Side-by-side comparison of Longeveron Inc. (LGVN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGVN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $171.01B, about 18432.1x LGVN ($9.3M).
- Over the past year, LGVN is down 63.5% and NVO is down 30.9% - NVO leads by 32.7 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for LGVN).
- NVO has more recent analyst coverage (25 ratings vs 2 for LGVN).
- Company
- Longeveron Inc.
- Novo Nordisk A/S
- Price
- $2.79-5.42%
- $38.38-1.07%
- Market cap
- $9.3M
- $171.01B
- 1M return
- -60.31%
- -17.04%
- 1Y return
- -63.53%
- -30.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 5
- Recent ratings
- 2
- 25
Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LGVN
- Longeveron Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
- Longeveron Inc. filed SEC Form 8-K: Other Events
- Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Chief Financial Officer Jhaveri Nirav S. was granted 300,000 shares (SEC Form 4)
- New insider Jhaveri Nirav S. claimed no ownership of stock in the company (SEC Form 3)
- Longeveron Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Longeveron Announces 1-for-10 Reverse Stock Split
- Chief Medical Officer Agafonova Nataliya was granted 286,000 shares, increasing direct ownership by 66% to 716,914 units (SEC Form 4)
- CTO & SVP of CMC Blass Devin was granted 286,000 shares, increasing direct ownership by 67% to 711,735 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S